Chronic granulomatous disease (CGD) is a rare congenital syndrome that results in severe, recurrent bacterial and fungal infections. The most common form is caused by defects in the CYBB gene, leading to the absence of gp91phox associated with totally abolished NADPH oxidase activity (X91 0 CGD). We report 3 brothers with atypical cases of X-linked CGD, characterized by low levels of expression of gp91phox (X91 Ϫ CGD). A point mutation (T-55C) identified in the CYBB gene's promoter region appears to prevent the full expression of this gene in neutrophils. This results in low levels of expression of gp91phox protein that are correlated with residual oxidase activity in the whole population of neutrophils. The total O 2 Ϫ production in these cells was ∼5% of normal. Despite this oxidase activity, the patients experienced severe and life-threatening infections. It was concluded that the O 2 Ϫ production in the neutrophils of these patients was not sufficient to protect them against infections, and this X91 Ϫ CGD phenotype must be considered to be a severe clinical form of CGD.
. Pedigree of family S. White symbols, no mutation at position Ϫ55 in CYBB; grey symbols, heterozygous T-55C mutation in CYBB; black symbols, male family members with T-55C in CYBB. The maternal grandmother (I2) and the mother (II2) are carriers of chronic granulomatous disease (CGD) (intermediate values in nitroblue tetrazolium (NBT) reduction test). Maternal uncles (II4 and II5) of patients A, B, and C are in good health, and the maternal aunt (II3) is under investigation and has no children. The daughter of patient A (IV1) is a carrier of the disease, and the son of patient C (IV1) is in good health (compare with [NADPH oxidase activity and cytochrome b 558 content in table 1). The respective wives (IIIa and IIIc) of patients A and C have been tested by NBT reduction and are not carriers of CGD (data not shown).
deep organs (lung, liver, bone, and brain) are frequent and are difficult to fight [13] . The majority of affected individuals receive a diagnosis early in life, but, in some rare cases, CGD is discovered during adulthood, when clinical signs are not severe and appear infrequently [14, 15] .
CGD is a very heterogeneous genetic disease caused by a large variety of mutations-such as deletions and splice-site, missense, or nonsense mutations-localized in the 4 genes encoding NADPH oxidase components, with no "hot-spot" localization, except for the NCF1 gene encoding p47phox protein [16] . There are 2 types of CGD transmission that make up autosomal forms (mutations in genes encoding p47phox, p67phox, or p22phox proteins) and the most common (60% of CGD cases) X-linked CGD type (defects in CYBB encoding gp91phox). The CYBB gene encompasses 13 exons spanning ∼30 kb of human X-chromosome genomic DNA. In the majority of cases, cytochrome b 558 is absent and no oxidase activity can be detected (X91 0 ) [16] [17] [18] [19] [20] [21] . A few rare cases of mutations in CYBB (!10%), resulting in low levels of expression of cytochrome b 558 , have been identified (X91 Ϫ ) [22] [23] [24] [25] [26] [27] [28] [29] [30] . In some cases, X91 Ϫ CGD results in weak oxidase activity detected in the entire population of neutrophils, weak activity that is related to low levels of expression of cytochrome b 558 [25, 28, 29] . Only 4 different mutations in the promoter region of CYBB that are related to CGD disease have been described [23, 26, 27, 30] . Mutations C-52T and C-53T have been reported to prevent the expression of gp91phox in neutrophils of patients with CGD and leave it intact in their eosinophils, which retained oxidase capacity [30] . This probably explains the relatively mild course of these CGD types. However, X91 Ϫ CGD due to T-55C or A-57C mutations, which are characterized by a small subset (5%-10%) of neutrophils expressing a near normal level of oxidase activity, have been described as severe clinical forms [23, 24] . In the 3 brothers described here, the neutrophil population had a diminished but measurable level of NADPH oxidase activity (3%-9% of normal). Neutrophils from these patients showed a homogeneous population, with slight O 2 Ϫ production related to low levels of expression of cytochrome b 558 (X91Ϫ CGD). We have examined the molecular defect in the 3 brothers, who have "variant" X-linked CGD. No mutations were found in the reverse-transcriptase (RT) polymerase chain reaction (PCR)-amplified fragments from gp91phox mRNA after sequence analysis. By amplification and sequencing of the corresponding genomic DNA, a point mutation was identified in the promoter region of CYBB, changing thymidine to cytosine at position Ϫ55 (T-55C). This mutation is located between the "CCAAT" and the "TATA" boxes in a consensus binding site for the ets family of transcription factors of the gp91phox promoter responsible for CYBB transcription [23] . Despite the low levels of expression of gp91phox protein and the residual NADPH oxidase activity in phagocytes, the clinical appearance of CGD in these 3 patients was severe, with multiple life-threatening infections occurring during their lives.
PATIENTS, MATERIALS, AND METHODS

Patients.
The pedigree of family S is depicted in figure 1 . Patient A was born in May 1976. Diagnosis of CGD was made when his brother, patient B, received a diagnosis. Patient A exhibited no complications of his immune defect until he was 11 years old. He first experienced an episode of bacterial pneumonia and then multiple hepatic abscesses that were successfully treated by antibiotics (1 g of oxacillin 4 times daily and 300 mg of rifampin twice daily). Staphylococcus aureus was involved in these 2 infections. Surgical treatment was required for new hepatic abscesses when he was 18 years old, and Klebsiella pneumonia was isolated from the pus; 2 g of ceftriaxone was administered intravenously (iv) 4 times daily with 500 mg of ciprofloxacin orally twice daily, for 2 months. Today, patient A is well and is undergoing prophylactic antibiotic and antifungal therapies (160 mg of cotrimoxazole and trimethoprim twice daily and 400 mg of itraconazole daily). Patient B was born in April 1978. Diagnosis of CGD was made when he was 8 months old. He had staphylococcal wrist arthritis. He previously had had recurrent carbuncles. Then he had minor infections, including repeated adenitis, bronchopneumonia, dental abscesses, and recurrent mouth ulcerations, but hospitalization was not required. The first major infection 1 ϫ 10 generation was determined by superoxide dismutase-inhibitable cytochrome c reduction assay. Neutrophils were activated with opsonized latex beads in presence of nitroblue tetrazolium (NBT). The reduction of NBT and the phagocytosis of latex beads were accessed by microscopy. Cytochrome b 558 content of neutrophils was measured by reduced minusoxidized difference spectra, as described in Patients, Materials, and Methods. Patients IV1 and IV2 are, respectively, the daughter of patient A and the son of patient C. The pedigree of family S is shown in figure 1. Nos. in parentheses are percentage of control values, unless otherwise noted. CGD, chronic granulomatous disease; ND, not done. occurred when he was 18 years old. It was a primitive femoral osteitis, which was treated with a single antibiotic for 8 months (200 mg of ofloxacin orally twice daily and 600 mg of rifampin twice daily). Two years later, he had hepatic abscesses that required drainage, needle puncture, and antibiotic therapy (4 g of piperellin-tazobactam three times daily and 200 mg of ciprofloxacin iv twice daily). Interferon (IFN)-g-1b was added to the antibiotic therapy (80 mg subcutaneously 3 times/week) over the next year. Recently (at 21 years old) he developed a disseminated candidiasis, with cutaneous localizations and positive blood cultures with liver and spleen involvement. Although this severe episode was controlled by fluconazole (800 mg iv, the first few days, followed by 400 mg orally), a bacteriemia due to Salmonella typhimurium occurred a few weeks later. Antibiotic therapy (200 mg of ofloxacin twice daily) was added to the previous antifungal therapy, and IFN-g was used again at the same dosage. Today, patient B is well and is undergoing prophylactic antibiotic and antifungal therapies associated with IFN-g.
Patient C was born in April 1979 and has a more severe medical history than his brothers did. Because he was the youngest child, diagnosis of CGD was made during the first week of life by a nitroblue tetrazolium (NBT) test. He showed early and frequent mouth ulcerations and adenitis. At 7 years old, he developed a viral meningomyelitis due to complications of Epstein-Barr virus (EBV) infection. The outcome was positive and free of sequelae. Five years later, he had severe pneumonia due to Aspergillus fumigatus. He was treated with amphotericin B (50 mg iv daily) for 6 months. This severe fungal pneumonia was followed by multiple hepatic abscesses (S. aureus) requiring surgical excision. New hepatic abscesses occurred 1 year later (Serratia marcescens), which were controlled by treatment with a single antibiotic (2 g of ceftriaxone iv four times daily with 500 mg ciprofloxacin orally twice daily, during a 3-month period). Today, he shows a delayed consolidation of a leg fracture and is receiving 160 mg of cotrimoxazole and trimethoprim twice daily and 400 mg of itraconazole daily, as a prophylactic regimen.
As seen in figure 1 Cell preparations. Human neutrophils and mononuclear cells (lymphocytes plus monocytes) were isolated from 25 mL of citrated or heparinized blood obtained from the patients, their parents, and healthy donors, as described elsewhere [31] , after their informed consent was obtained. Lymphocytes from 5 mL of heparinized sterile venous blood were collected by Ficoll-Hypaque density gradient centrifugation and were infected with the B95-8 strain of EBV, as described elsewhere [32] . The EBV-B lymphocyte cell line was grown in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 50 mg/mL streptomycin, at 37ЊC in a 5% CO 2 atmosphere.
NBT reduction and phagocytosis slide test. The phagocytic capacity and the O 2 Ϫ production of the neutrophils from the patients, their relatives, and healthy donors were estimated by NBT reduction and opsonized latex bead phagocytosis slide tests [33] . Also, cells were activated with PMA. Superoxide assay. NADPH oxidase activity of intact neutrophils was assessed by measuring the rate of superoxidesensitive cytochrome c reduction at 550 nm (e 550
, in the presence of superoxide dismutase (SOD) [32] . Flow cytometric detection of peroxide in purified granulocytes. To evaluate cellular hydrogen peroxide levels, dihydrorhodamine (DHR)-loaded, purified granulocytes (1 ϫ 10 6 cells) were stimulated with 20 ng/mL PMA for 10 min at 37ЊC, in accordance with the manufacturer's instructions (Phagoburst; Orphagen Pharma). The reaction was stopped with 2 mL of cold washing solution. After 2 washes, cells were resuspended and were analyzed by flow cytometry (FACScalibur; Becton Dickinson). Dead cells and debris were excluded from the analysis by use of forward and side scatter. For each tube, 10,000 events were collected and were analyzed by Cell Quest software (BD PharMingen). All experiments were performed in triplicate.
Simultaneous assessment of CRTH2 receptor and gp91phox protein by flow cytometry. Granulocytes ( cells) were 5 5 ϫ 10 resuspended in 100 mL of PBS containing 2% (p/v) bovine serum albumin and 1 mmol/L CaCl 2 . This buffer was used in each washing step. Cells were incubated with 10 mL of PEconjugated MAbs against CRTH2 receptor [34, 35] or control monoclonal IgG2A, for 15 min at room temperature. Cells were washed twice and were incubated with 10 mg/mL MAbs directed against gp91phox (7D5) [36] or control monoclonal IgG1, for 30 min on ice. The cells were washed again and were incubated with fluorescein isothiocyanate-conjugated goat-F(ab ) 2 against mouse IgG1 (Caltag Laboratories). Finally, cells were washed and kept on ice until flow cytometry analysis (FACScalibur). Data were collected from 10,000 events by CellQuest software (BD PharMingen). Electronic compensation was FL2-FL1 of 15%. All experiments were performed in triplicate.
Preparation of RNA and DNA. Total RNA was isolated from both native mononuclear cells and EBV-transformed B lymphocytes from patients with CGD, as well as from healthy donors, by use of a modified single-step method described elsewhere [37] , performed with TriZol reagent. Genomic DNA was purified from mononuclear cells and EBV-transformed B lymphocytes from patients with CGD and from healthy donors, after performance of classic procedures [38] .
cDNA amplification. First-strand cDNA synthesis was performed from total RNA by use of a cDNA synthesis kit in accordance with the manufacturer's instructions (Appligen Oncor). The cDNA of gp91phox was immediately amplified by PCR, as described by Stasia et al. [39] .
Sequencing of the PCR products. PCR products were gelpurified and were sequenced by Genome Express, with forward and backward primers, by use of the ABI Prism automatic sequencer (Perkin-Elmer) [40] . PCR products were obtained from cDNA or genomic DNA of patients A, B, and C and their parents, prepared from mononuclear cells or EBV-B lymphocytes.
Gp91phox promoter region amplification. Genomic DNA purified from peripheral blood mononuclear cells or EBV1-immortilized B lymphocytes was amplified with the forward primer P1 CAGCAAGGCTATGAATGCTGTTC (position Ϫ427 in the CYBB promoter region) and the backward primer P2* GGAGAGCCCCTCATTCACAG (position +45) [41] .
Cytochrome b 558 spectroscopy. Purified neutrophils treated with 3 mmol/L diisopropyl fluorophosphate were lysed for cytochrome b 558 extraction, as described elsewhere [42] . The supernatant was used for immunoblotting experiments and cytochrome b 558 spectroscopy. Reduced minus-oxidized difference absorption spectra were recorded at room temperature by a DU 640 Beckman spectrophotometer [43] . A molecular extinction coefficient of e 426-427 mmol/L Ϫ1 ϫ cm Ϫ1 nm p 106 for the Soret band was used for calculations.
SDS-PAGE and immunoblotting.
Proteins solubilized from neutrophils, in 1% Triton X-100, were separated by SDS-PAGE in 10% (wt/vol) polyacrylamide gel with a 5% (wt/vol) stacking gel [44] , were electrotransferred to nitrocellulose [45] , and were immunodetected by MAbs 449 and 48 directed against p22phox and gp91phox, respectively [46] , or by polyclonal antipeptide antibodies directed against p47phox and p67phox proteins [47] . Detection was mediated with horseradish peroxidase-labeled goat anti-rabbit or anti-mouse IgG, followed by a chemiluminescence reaction (ECL detection system; Amersham). The film's exposure time was !1 min.
Protein determination. The protein content was estimated by the Bradford assay [48] . 1 ϫ 10 opsonized latex beads, in the presence of NBT dye, as described in Patients, Materials, and Methods. The percentage of neutrophils that phagocytose the latex beads and reduce the NBT were counted by microscopy. Neutrophils from patient C were stimulated with opsonized latex beads without NBT (C). The same test was performed with neutrophils from patients A and B (data not shown). Arrows indicate violet formazan precipitates.
RESULTS
Diagnosis of CGD for patients
NBT (figure 2D). Each cell had only a few grains of violet formazan precipitate, rather than the heavy deposits seen in those from the healthy donor ( figure 2B and 2D ). Patient C's neutrophils had a uniformly weak staining, unlike the absence of NBT reduction in the more common form of X-linked CGD (X91 0 ) ( figure 2A and 2D ). The same result was observed when cells were stimulated with PMA. Similar results were obtained from patients A and B (data not shown). The result of the NBT slide test on their mother's neutrophils (60% of her neutrophils intensively reduced the NBT with normal phagocytosis) confirmed that she is a carrier of the disease. This mode of inheritance supported an X-linked mutation, because the daughter of patient A (IV1) is a carrier, and the son of patient C (IV2) is normal. Purified neutrophils from their father have normal phagocytosis of opsonized latex beads and NBT reduction, compared with the healthy donor's neutrophils (table 1) .
To confirm the defect in O 2 Ϫ production, NADPH oxidase activity was measured by the SOD-sensitive cytochrome c reduction test, in purified neutrophils from patients A, B, and C ( figure 3 ). Neutrophils were stimulated with a soluble stimulus PMA (20 ng/mL), and the specificity of the reaction was evaluated by addition of SOD (10 mg/mL) at the end of the kinetic reaction. As seen in figure 3 , the respiratory burst measured in the neutrophils of patients A, B, and C was very low (0.48, 0.33, and 1.1 nmol/min/10 6 cells, respectively), compared with the O 2 Ϫ production in purified neutrophils from the healthy donor (11.8 nmol/min/10 6 cells). In contrast, no NADPH oxidase activity was detected in neutrophils from the patient with X91 0 CGD. This result is representative of 3-6 different experiments. The mean ‫ע‬ SD NADPH oxidase activity is shown in table 1. These values for the patients' neutrophils represent 3%-9% of the total NADPH oxidase activity of control neutrophils.
Flow cytometric detection of hydrogen peroxide production in granulocytes was measured by the DHR oxidation assay ( figure 4A ). Patient C's granulocytes ( figure 4A, bottom) showed a unique activity peak after stimulation with PMA (20 ng/mL), with a mean fluorescence intensity of 33 arbitrary units (AU), compared with that for those from the healthy donor (1935 AU) ( figure 4A, top) . In our conditions of measurement, 70% of the healthy donor's granulocytes showed maximal activation ( figure 4A, top) . The mean fluorescence intensity of patient C's granulocytes was 10-fold higher than that in the resting control cells and 58-fold lower than that in the same activated cells.
No positive granulocyte population was detected in the patient with X91 0 CGD (4 AU) after PMA stimulation ( figure 4A,  middle) .
Identification of granulocyte population and membrane expression of cytochrome b 558 were checked by double-staining flow cytometric analysis (figure 4B). The specificity of the MAbs against the CRTH2 receptor was evaluated by a granulocyte preparation containing 20% eosinophils, determined by morphological criteria, obtained from a hypereosinophilic patient. The PE-coupled MAbs against CRTH2 receptor stained only the eosinophils, representing 22% of total granulocytes (CRTH2 + population) ( figure 4B, bottom right) . In granulocytes from a healthy donor ( figure 4B, top left) , a patient with X91 0 CGD ( figure 4B, top right) , and patient C (figure 4B, bottom left), the percentage of eosinophils was 2%. Surface expression of gp91phox protein revealed by the 7D5 binding to granulocytes showed 2 cell populations in the granulocyte preparation from a hypereosinophilic patient: 1 corresponding to neutrophils (78%) and the other corresponding to eosinophils (22%) ( figure 4B, bottom right) . The granulocyte preparation from a healthy donor also showed 2 cell populations with high 7D5 binding: 1 (CRTH2 Ϫ ) corresponding to neutrophils (98%) and the other (CRTH2 + ) corresponding to eosinophils (2%) ( figure 4B, top left) . From the patient with X91 Ϫ CGD ( figure 4B, bottom left) , 2% of granulocytes expressing CRTH2 and gp91phox were characterized as eosinophils. Likewise, the level of eosinophils in patient C's granulocytes was very low (2%), making the detection, by flow cytometric analysis, of oxidase activity in these cells difficult ( figure 4A, bottom) . For the patient with X91 0 CGD (figure 4B, top right), this population, also representing 2% of granulocytes, was CRTH2 + and 7D5
Ϫ . No 7D5 binding was measured in neutrophils from the patient with X91 0 CGD related to the absence of cytochrome b 558 expression and O 2 Ϫ production ( figure 4B, top right) . In the case of patient C ( figure 4B, bottom left) , despite the low but measurable levels of NADPH oxidase activity in his granulocytes, as shown above, gp91phox was not detected in the CRTH2 Ϫ population (97%). The level of gp91phox protein expressed in each neutrophil was probably too low, making its detection impossible by flow cytometry. The same results were obtained from patients A and B (data not shown).
To demonstrate the presence of cytochrome b 558 in the patients' neutrophils, Western blot analysis and reduced minusoxidized difference spectra were performed in 1% Triton X-100 soluble extract. As illustrated in figure 5A and table 1, difference spectra revealed a low level of cytochrome b 558 (2-5 pmol/mg proteins) in the neutrophils of patients A, B, and C, compared with the soluble extract from a healthy donor (110 ‫ע‬ 30 pmol/mg proteins). In contrast, the spectrum of X91 0 CGD neutrophils did not have the g, b, and a peaks characteristic of cytochrome b 558 . The cytochrome b 558 content in patients A, B, and C was 2%-5% of the normal neutrophils. The presence of a low level of cytochrome b 558 in the neutrophils of these patients was confirmed by the results of Western blot analysis that used an identical amount of 1% soluble extract in all samples (50 mg), as seen in figure 5B. We illustrated the low level of the heavy chain of cytochrome b 558 (gp91phox) and the light chain subunit a (p22phox), in the content of patients A, B, and C, compared with that in the healthy donor's content. The specificity of MAbs directed against the 2 subunits was demonstrated by the absence of gp91phox and p22phox in the X 0 CGD-soluble extract, compared with that in the control neutrophils. A similar experiment was performed with antibodies directed against the cytosolic factors p67phox and p47phox, with an identical result occurring in all samples (data not shown). The above results suggest that the phenotype was compatible with a mutation located in CYBB encoding gp91phox, leading to a low level of expression of cytochrome b 558 , as found in the X91 Ϫ CGD type.
Genetic analysis of patients A, B, and C.
RT-PCR and sequence analyses were performed to localize the mutation in the mRNA encoding gp91phox. The mRNAs of healthy donors and patients were reverse-transcribed into 3 overlapping cDNA fragments, with 3 pairs of oligonucleotide primers derived from the gp91phox cDNA, and were sequenced as described else- where [39] . No mutation in the cDNA of gp91phox protein was found. A part of the gp91phox promoter region in genomic DNA (CYBB) was amplified by PCR using the 2 primers described in Patients, Materials, and Methods. By use of sequence analysis, a point mutation was found to be localized at position Ϫ55, changing a thymidine to a cytosine in patients A, B, and C, as seen in figure 6A . This mutation is localized in a region between the "CCAAT" and the "TATA" boxes in a consensus binding site for the ets family of transcription factors of the gp91phox promoter responsible for CYBB transcription (figure 6B). Fifty control genomic DNA were checked, and no mutations were found for the father of patients A, B, and C.
Clinical appearance of CGD in patients A, B, and C. Details of the clinical history of the 3 brothers are described in case reports. Some characteristics of family S must be emphasized. The 3 brothers have always been treated in the same medical center. The medical histories of patients A, B, and C are comparable, including severe and recurrent pneumonia or hepatic abscesses. All 3 patients exhibited у1 life-threatening infection. Their CGD must be considered to be a clinically severe form of the disease.
DISCUSSION
Here, we have reported 3 cases of identical, rare X-linked CGD in which cytochrome b 558 is expressed at low levels, as measured by immunoblotting and difference absorption spectra, levels that are correlated with weak production of superoxide anion in neutrophils (X91 Ϫ CGD). That patient A has a daughter (IV1) with carrier status, as does his mother (II2), and that patient C has a healthy son (IV1) confirms an X-linked transmission of the disease ( figure 1 and table 1 ). X-linked CGD is the most common form of this disease (∼60% of cases), and, generally, cytochrome b 558 (including gp91phox and p22phox proteins) is absent from patients' neutrophils, and NADPH oxidase activity is totally abolished (X91 0 CGD) [16] . Occasionally, variant forms of X-linked CGD, called X91 Ϫ CGD, occur, in which low levels of cytochrome b 558 and proportionately decreased oxidase activity appear in phagocytes. Mutations that are associated with this phenotype are usually located in exons of CYBB [25, 28, 29] . These variants are of interest because they result from structural disorganization, leading to an incomplete loss of protein, partial dysfunction, or both. As seen in figure 2 , phagocytes from patient C have a slight ability to reduce the NBT dye when they are stimulated with opsonized latex beads ( figure 2D ). The violet formazan coloration is very weak and is uniform, compared with normal phagocytes in which heavy deposits can be observed ( figure  2B ). It seems that proportionately decreased oxidase activity is expressed uniformly in all phagocytes. The same result was obtained from patients A and B when cells were stimulated with PMA instead of opsonized latex beads (data not shown). The NADPH oxidase activity in the neutrophils of patients A, B, and C is confirmed by the SOD-sensitive cytochrome c reduction assay, as seen in figure 3 and table 1. The respiratory burst of these patients' neutrophils is 3%-9% of normal. Flow cytometric analysis of DHR oxidation in patient C's neutrophils also confirms the presence of a homogeneous population with a low level of oxidase activity, as observed by the NBT reduction test. The mean fluorescence intensity is increased 10-fold when PMA is added and represents 2% of normal ( figure 4A ).
In the study by Woodman et al. [24] , flow cytometric analysis of DHR oxidation was performed in granulocytes from patients with X91
Ϫ CGD with Ϫ55 or Ϫ57 mutations characterized elsewhere [23] . They also obtained a homogeneous activatedneutrophil population with a mean fluorescence intensity 5-fold higher than that in resting cells; the neutrophils of a patient with X91 0 CGD had no oxidase activity. They focused on a 5%-10% granulocyte population with a variable fluorescence intensity (10 2 -10 4 AU), which they considered to be neutrophils with normal oxidase activity. This subgroup of granulocytes had a high NBT reduction capacity when activated with PMA and perhaps were eosinophils. Unfortunately, the authors never mentioned the percentage of eosinophils in the granulocyte preparation. All the granulocytes of a patient with X91 0 CGD exhibited a visible NBT reduction, but, surprisingly, no reduction appeared in the granulocytes of a patient with X91 Ϫ CGD, other than the subgroup of 5%-10% with normal oxidase activity.
As we know, NBT reduction is not absolutely specific to NADPH oxidase activity, and the visible background in the granulocytes of patients with X91 0 CGD may be due to a non- Figure 6 . Analysis of mutations in the CYBB gene. Polymerase chain reaction products were gel-purified and automatically sequenced by Genome Express, with forward and backward primers P1 and P2*, as described in Patients, Materials, and Methods. A, Point mutation detected in the gp91phox promoter region at position Ϫ55, changing a thymidine to a cytosine, for patients A, B, and C, compared with a control sequence. B, Schematic representation of part of the gp91phox promoter region, with localization of the point mutation described in A, the "CCAAT" and "TATA" boxes, and the ATG starting codon.
specific reduction. However, this raises the question of why this phenomenon does not occur in the case of patients with X91 Ϫ CGD. Weening et al. [30] have demonstrated that these kinds of point mutations, which are found in the CYBB promoter region, prevented the expression of gp91phox in patients' neutrophils and thus made these cells incapable of generating oxygen radicals but left the gp91phox expression and the function of eosinophil NADPH oxidase intact. In a later study, the percentage of eosinophils was elevated (20% and 26%) and may explain the mild clinical forms seen in their patients with CGD. Yet different studies [49] [50] [51] have demonstrated that transcription factors GATA-1, GATA-2, and GATA-3 are implicated in eosinophil-specific regulation of gp91phox expression, but not in neutrophilic, monocytic, or B-lymphocytic cells. The composition of the granulocyte preparation from patient C was checked by double-staining flow cytometric analysis, to simultaneously assess cytochrome b 558 and CRTH2 receptor of eosinophils ( figure 4B ). Granulocytes of patient C contain 2% eosinophils (the same result was obtained by morphological criteria), which are also revealed by the MAb 7D5. This low level does not explain the respiratory burst measured in these cells (9% of normal) (table 1) . Nevertheless, the presence of eosinophils in the granulocyte population has not been proven to be a consequence of the mutation in the gp91phox promoter, because the same low level of these cells (2%) is present in the granulocytes from patients with X91 0 and from patients with X91 Ϫ CGD, as well as in those from the healthy donor. In the neutrophil population from patient C (CRTH2 Ϫ ), cytochrome b 558 could not be detected, probably because the level of gp91phox expressed at the surface of each cell is low and is under the sensitivity limit of flow cytometry. Similar results were obtained with the granulocytes of patients A and B (data not shown). Yet cytochrome b 558 is present in the 1% Triton X-100 soluble extract, as assessed by difference spectra and Western blot analysis. These 2 techniques make it possible to concentrate the cytochrome b 558 content and to detect it in 10 6 equivalent cells (or 50 mg of proteins). In the neutrophils of patients A, B, and C, the 2 subunits of cytochrome b 558 are both expressed in low amounts ( figure 5B ). This can be explained by the fact that cytochrome b 558 is a heterodimer of p22phox and gp91phox proteins, which are usually missing in A22 0 CGD as well as in X91 0 CGD, probably because these 2 subunits stabilize each other [52] .
The genetic defect in CYBB encoding gp91phox protein in patients A, B, and C is a point mutation in the CYBB promoter region, localized by PCR amplification and sequence analysis (figure 6). The mutation is located at Ϫ55, in a region between the "CCAAT" and the "TATA" boxes in a consensus binding for the ets family of transcription factors of the gp91phox promoter site (5 -GAGGAAAT-3 , lower strand, Ϫ57 to Ϫ50 bp). To our knowledge, only 4 point mutations have been described in patients with CGD, corresponding to the Ϫ52, Ϫ53, Ϫ55, and Ϫ57 positions [23, 26, 27, 30] . In cotransfection experiments, Elf-1 and PU.1, members of the ets family of transcription factors abundantly expressed in myeloid cells, bind to the later ets binding sequence and transactivate the promoter [26, 27] . Interestingly, Ϫ57, Ϫ55 (as in patients A, B, and C), and Ϫ53 mutations strongly inhibit the binding of both factors, suggesting that these mutations reduce gp91phox promoter activity, leading to a low level of expression of gp91phox protein [26, 27] . These results suggest that Elf-1 and PU.1 contribute to direct the lineage-restricted expression of the gp91phox gene in phagocytes. Newburger et al. have described that Ϫ55 mutation leads to a decrease in gp91phox mRNA [23] . This phenomenon can explain the low levels of expression of gp91phox protein, levels that are correlated with a reduced NADPH oxidase activity in the patients' neutrophils. Yet it is not clear how the binding of Elf-1 and/or PU.1 to this full consensus sequence (Ϫ57 to Ϫ50) can influence the transcription initiation by RNA polymerase II. Analysis of PU.1-associated factors should lead to additional mechanisms implicated in gp91phox gene expression. These X91
Ϫ CGD with Ϫ57 and Ϫ55 mutations in the gp91phox promoter resulted in a clinically severe phenotype [23, 24] . According to the total NADPH oxidase activity measured in their neutrophils (3%-9% of normal), patients A, B, and C can be compared with X-linked carriers exhibiting the same amount of O 2 Ϫ production because of extremely unbalanced X-chromosome inactivation [53] . In general, these carriers are free from infections or have mild infectious complications, although some may display the full-blown expression of the disease. Despite the slight NADPH oxidase activity in their neutrophils, patients A, B, and C experienced a severe clinical form of CGD and presented multiple life-threatening infections in deep organs. These different phenotypes, which are associated with the same total NADPH oxidase activity in neutrophils, can be explained by the fact that, in X-linked carriers, 5%-10% of neutrophils exhibit normal respiratory burst, which normally can fight microorganisms and can protect carriers against infections. A comparable situation can exist in the patients with X91 Ϫ CGD, described elsewhere [30] , with a high level of eosinophils (15%) exhibiting normal NADPH oxidase activity. Nevertheless, the compensatory mechanism by which the eosinophils are overproduced is unknown. In the case of patients A, B, and C, each neutrophil has a very low level of NADPH oxidase activity (as shown by NBT reduction test and by flow cytometric analysis with DHR oxidation), and the O 2 Ϫ production is not sufficient to kill foreign microorganisms during infections. In a recent study, Reeves et al. [54] proposed a new killing mechanism of neutrophils mediated through activation of proteases by K + flux. In a previous report, Talkevic et al. [55] showed that, despite normal neu-trophil development and recruitment, mice deficient in the neutrophil granule serine proteases (elastase and cathepsin G) were susceptible to fungal infections. We can speculate that the superoxide production in the neutrophils of the patients with X91
Ϫ CGD described here is not sufficient to provoke influx of K + as a compensatory charge process that is responsible for the release and the activation of cationic granule proteins. Consequently, the killing of microorganisms by these proteases is defective. The mechanism by which proteases are activated in the neutrophils of patients A, B, and C are currently under investigation in our laboratory. This finding has also been illustrated in an article by Bu-Ghanim et al. [25] that describes 3 cases of X91
Ϫ CGD in patients with a missense mutation or small in-frame deletions. The killing of S. aureus by cells from 1 of the patients with CGD was markedly defective and was comparable with the levels observed in cells from a patient with X91 0 CGD, even though their granulocytes were able to produce superoxide, albeit in small amounts (12% of normal). All 3 patients expressing uniform and low levels of oxidase activity in their granulocytes received early diagnoses and experienced numerous infections requiring hospitalization. The general idea is that patients with X91
Ϫ CGD with missense mutations receive a diagnosis later in life than do patients with X91 0 CGD and have a milder clinical course [13] .
We believe that the number of published cases of X91 Ϫ CGD with both a well-documented clinical history and knowledge of the genetic lesion is not high enough to provide a clear and definitive opinion on the severity of the clinical course of these variants. In addition, the severity of CGD depends not only on the subtype of the disease, but also on polymorphisms in genes other than oxidase genes. The best illustration is the discrepancy between the worst clinical profile of patient C and the NADPH oxidase activity of his granulocytes, which remains higher than that of his brothers (9% vs. 3%-5% of normal) (table 1) . Other pathways are implicated in the first-line defense mechanism against microbial pathogens of the mammalian host. For example, the Toll-like receptor activation [56] , in particular the Toll/interleukin-1 (IL-1)-IL-1 receptor-associated kinase signaling pathway, seems to be crucial for protective immunity against specific bacteria [57] .
In conclusion, in the 3 cases of X91 Ϫ CGD reported here, infections and severe clinical complications occurred, even in the presence of a low but significant O 2 Ϫ -generating oxidase activity and with constant care and follow-up at a single medical center with the same physician. In such cases, the follow-up of patients depends on early diagnosis and prophylactic antibiotic and antifungal therapies in association with IFN-g injection [58, 59] . Systematic characterization of gene mutations in patients with CGD should help us to relate the clinical form to the type of gene affected and/or the type of mutation found in this disease. It can also be essential in genetic counseling and prenatal diagnosis. Although variant forms of CGD are rare, they contribute to our understanding of oxidase complex and of killing mechanisms in phagocytic cells.
